OmniAb Inc
OABI1.660USD
+0.040+2.47%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
203.68MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über OmniAb Inc Unternehmen
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.
Unternehmensinformationen
BörsenkürzelOABI
Name des UnternehmensOmniAb Inc
IPO-datumOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Anzahl der mitarbeiter114
WertpapierartOrdinary Share
GeschäftsjahresendeOct 09
Addresse5980 Horton Street
StadtEMERYVILLE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94608
Telefon15102507800
Websitehttps://www.omniab.com/
BörsenkürzelOABI
IPO-datumOct 09, 2020
CEOMr. Matthew William (Matt) Foehr
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Charles Stuart Berkman, J.D.
Mr. Charles Stuart Berkman, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
Dr. Jennifer Cochran, Ph.D.
Dr. Jennifer Cochran, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven C. Crouse
Mr. Steven C. Crouse
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John L. Higgins
Mr. John L. Higgins
Chairman of the Board
Chairman of the Board
2.85M
+0.71%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Executive Vice President - Finance, Chief Financial Officer
Executive Vice President - Finance, Chief Financial Officer
223.83K
-12.04%
Dr. Carolyn R. Bertozzi, Ph.D.
Dr. Carolyn R. Bertozzi, Ph.D.
Independent Director
Independent Director
75.54K
+36.01%
Mr. Steven (Steve) Love
Mr. Steven (Steve) Love
Independent Director
Independent Director
58.33K
+52.17%
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Matthew William (Matt) Foehr
Mr. Matthew William (Matt) Foehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
License and milestone revenue
2.02M
48.65%
Service revenue
1.95M
46.82%
Royalty revenue
188.00K
4.53%
Aktionärsstatistik
Aktualisiert: Mon, Sep 8
Aktualisiert: Mon, Sep 8
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Avista Capital Holdings, LP
12.89%
Whitefort Capital Management, LP
8.35%
Ash X LP
6.74%
BlackRock Institutional Trust Company, N.A.
5.16%
The Vanguard Group, Inc.
4.29%
Andere
62.57%
Aktionäre
Aktionäre
Anteil
Avista Capital Holdings, LP
12.89%
Whitefort Capital Management, LP
8.35%
Ash X LP
6.74%
BlackRock Institutional Trust Company, N.A.
5.16%
The Vanguard Group, Inc.
4.29%
Andere
62.57%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
16.49%
Hedge Fund
14.30%
Investment Advisor/Hedge Fund
12.94%
Private Equity
12.89%
Corporation
8.21%
Individual Investor
6.67%
Research Firm
1.02%
Pension Fund
0.14%
Venture Capital
0.11%
Andere
27.24%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
348
92.68M
75.53%
-5.84M
2025Q1
359
87.33M
71.43%
-8.58M
2024Q4
365
89.85M
74.79%
-8.38M
2024Q3
394
90.25M
75.21%
-25.05M
2024Q2
389
89.07M
76.08%
-29.09M
2024Q1
378
93.24M
79.93%
-23.55M
2023Q4
374
92.06M
79.14%
-28.03M
2023Q3
352
92.71M
80.23%
-26.22M
2023Q2
337
91.30M
79.07%
-24.17M
2023Q1
319
89.47M
77.82%
-24.53M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Avista Capital Holdings, LP
15.82M
12.93%
--
--
Sep 30, 2024
Whitefort Capital Management, LP
7.31M
5.98%
+3.40M
+86.81%
May 30, 2025
Ash X LP
1.09M
0.89%
+1.09M
--
Jun 12, 2025
BlackRock Institutional Trust Company, N.A.
6.46M
5.28%
+62.83K
+0.98%
Mar 31, 2025
The Vanguard Group, Inc.
5.18M
4.23%
+142.26K
+2.82%
Mar 31, 2025
Foehr (Matthew W)
3.80M
3.1%
-13.61K
-0.36%
Apr 23, 2025
Dimensional Fund Advisors, L.P.
3.13M
2.56%
+106.04K
+3.50%
Mar 31, 2025
Higgins (John L)
2.85M
2.33%
+20.00K
+0.71%
Jun 17, 2025
Rice Hall James & Associates, LLC
2.58M
2.11%
-68.23K
-2.58%
Mar 31, 2025
Private Management Group, Inc.
2.53M
2.07%
+296.71K
+13.29%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Sep 6
Aktualisiert: Sat, Sep 6
Name
Anteil
iShares Morningstar Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Morningstar Small-Cap Value ETF
0%
Dimensional US Core Equity 1 ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
WisdomTree US SmallCap Fund
0%
iShares Genomics Immunology and Healthcare ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Mehr Anzeigen
iShares Morningstar Small-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
iShares Morningstar Small-Cap Value ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
WisdomTree US SmallCap Fund
Anteil0%
iShares Genomics Immunology and Healthcare ETF
Anteil0%
Fidelity MSCI Health Care Index ETF
Anteil0%
Fidelity Small-Mid Multifactor ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
